T

Tandem Diabetes Care

Develops subcutaneous insulin pumps and software

International Distributor Operations Specialist

Full-TimeUpdated on 10/21/2026
No salary listed
Mid
Bachelor's
Weert, Netherlands
HybridHybrid in Weert; on-site 2–3 days per week. International travel up to 25%.
Operations & Logistics

About the job

Requirements
  • A bachelor's degree, or an equivalent combination of education and relevant professional experience.
  • At least three years of experience in operations, supply chain, sales support, or a related environment.
  • Hands-on experience with order processing and forecasting or demand planning.
  • Proficiency with Microsoft Office and Microsoft Teams, together with working knowledge of customer relationship management systems, Salesforce, enterprise resource planning systems, Microsoft Dynamics, and other order management systems.
  • Strong spoken and written English, with clear communication, presentation, and interpersonal skills.
  • The ability to work accurately, use initiative, manage multiple priorities, and respond calmly and confidently to changing situations.
  • Experience working effectively across cultures and communicating with customers by phone and in writing.
  • Experience training customers at different organizational levels.
  • Fluency in English and any additional European languages.
Responsibilities
  • Coordinate distributor purchase orders from receipt through order entry, release, shipment, and completion.
  • Review orders for accuracy, completeness, pricing, product availability, allocation requirements, requested delivery dates, and alignment with forecast assumptions.
  • Monitor open orders and identify risks, delays, shortages, holds, pricing discrepancies, and other fulfillment exceptions.
  • Coordinate order changes, cancellations, partial fulfillment, and split shipments, ensuring updates are accurately recorded and clearly communicated.
  • Partner with Supply Chain, the European Distribution Center, and fulfillment teams to clarify inventory availability and expected delivery timing.
  • Serve as a primary operational contact for assigned distributor partners, providing updates on order status, product availability, shipment timing, delays, and allocation constraints.
  • Maintain allocation trackers, operational documentation, price lists, and accurate order data across Salesforce, CRM, ERP, Microsoft Dynamics, and other applicable systems.
  • Develop and analyze open-order, backlog, allocation, and fulfillment reporting, providing regular visibility to International Operations leadership.
  • Investigate recurring fulfillment issues and distributor concerns, identify root causes, and work with colleagues on corrective actions and continuous improvements.
  • Support internal order requests and coordinate with Regulatory Affairs on country-specific distribution changes for new product releases.
  • Work flexibly across international time zones and travel internationally as required, with travel of up to 25%.

About the company

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Get referred to Tandem Diabetes Care

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 international Mobi rollout added twelve markets and immediate shipment.
  • Q2 2026 revenue reached $254.6 million; full-year guidance stayed at $1.065-1.085 billion.
  • Pharmacy sales hit 10% of U.S. sales in Q2 2026, improving recurring revenue.

What critics are saying

  • FDA recall Z-0427-2026 on Mobi software exposed Malfunction 12; trust damage persists through 2026.
  • Class 2 t:slim X2 recall on January 30, 2026 showed translation-control failures.
  • Insulet and Dexcom pressure pricing, while Tandem still carries $300 million 2032 notes.

What makes Tandem Diabetes Care unique

  • Tandem Mobi is the world’s smallest durable AID system, launched September 2026.
  • Control-IQ+ now covers pregnancy in type 1 diabetes and adults with type 2.
  • Remote software updates and interoperable CGM support keep t:slim X2 and Mobi relevant.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Holidays
  • 401(k) Company Match
  • Remote Work Options
  • Hybrid Work Options
  • Employee Stock Purchase Plan
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo
Oct 19th, 2026
FDA clears Sequel's insulin delivery system in Type 2 diabetes.

FDA clears Sequel's insulin delivery system in Type 2 diabetes. Nick Paul Taylor Mon, October 19, 2026 at 4:05 AM PDT Dive brief: * The Food and Drug Administration has cleared the Twiist automated insulin delivery, or AID, system for use in adults with insulin-treated Type 2 diabetes. * Sequel Med Tech, which sells the device, disclosed the 510(k) clearance on Friday. The FDA granted the clearance to Deka Research and Development, Sequel's partner on Twiist. * The FDA cleared Twiist after researchers linked the AID system to reduced blood sugar and increased time in the target glycemic range in a clinical trial. Dive insight: Deka received clearance for the system in Type 1 diabetes in March 2024. Sequel launched the product nationally in the indication two years later. The latest clearance will enable immediate prescribing of the system for Type 2 diabetes patients, Sequel said. The product's algorithm is based on Tidepool Loop, a patient-led automated insulin dosing tool that received 510(k) clearance in 2023. Combining Deka drug delivery technology with the Loop algorithm positioned Sequel to compete for the AID market, initially in Type 1 diabetes. Sequel disclosed the label expansion shortly after researchers published pivotal data on the system in Type 2 diabetes patients. Mean blood sugar fell from 8.1% at baseline to 7.4% after 13 weeks using the AID system. The percentage of time patients spent in the targeted blood sugar range increased from 57% to 73%. Patients were more satisfied with the system than with their old insulin delivery method and reported improved sleep quality. Most patients had no experience with AID systems or carb counting at the start of the trial. Despite not being familiar with the technology, many patients experienced improved time in range within 24 hours of starting to use the AID system. Clinical data show Twiist "can deliver the kind of burden-free improvement this community has long needed," Joslin Diabetes Center's Dr. Osama Hamdy said in a statement. The system adjusts basal insulin based on targets set by the user and their care team. Beta Bionics, Insulet, MiniMed and Tandem Diabetes Care sell rival AID systems. Like its rivals, Sequel has integrated its technology with continuous glucose monitors. Twiist is compatible with Abbott's FreeStyle Libre 3 Plus sensor and Senseonics' Eversense 365. Recommended Reading

Business Wire
Sep 28th, 2026
Tandem Mobi automated insulin delivery system launches in 12 European markets

Tandem Diabetes Care has launched its Tandem Mobi automated insulin delivery system in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom. Tandem Mobi is described as the world's smallest durable automated insulin delivery system. It uses Control-IQ+ technology and a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every five minutes. The system offers mobile app control through compatible iPhones, multiple wear options, and a 200-unit cartridge. Android compatibility is expected in select countries in 2027.

6ix
Sep 28th, 2026
Tandem Mobi automated insulin delivery system now available in twelve international markets.

Tandem Mobi automated insulin delivery system now available in twelve international markets. Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes,[1] is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom. Tandem Mobi, the world's smallest, durable insulin delivery system, now shipping in multiple international markets. Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,[*] and a 200-unit cartridge. Control-IQ+ technology has been evaluated in studies of people with type 1 diabetes, type 1 diabetes during pregnancy, and type 2 diabetes, including studies published by the and the, with results showing immediate and sustained glycemic improvements, including more time in range and improved sleep. J NextS SaveEsc Close Scroll

The Diabetes Times
Sep 10th, 2026
Abbott's Libre established as the "most connected CGM in the world"

Abbott's Libre established as the "most connected CGM in the world" 10th September 2026 Abbott today announced the integration of its FreeStyle Libre 3 Plus sensor with Insulet's Omnipod(R) 5 Automated Insulin Delivery (AID) System in the UK, further expanding connected care options for people living with Type 1 diabetes who use a Libre sensor. The full UK availability of this latest integration builds on Abbott's FreeStyle Libre 3 Plus sensor and Tandem Diabetes Care's t:slim X2 insulin pump integration, which became available this summer. Based on the number of pump users having the ability to connect with Libre technology globally these latest partnerships establish Libre as the most connected continuous glucose monitoring (CGM) technology in the world*, providing users with access to more pump options globally than any other CGM. Today, in the UK, Abbott's connected diabetes management solutions are compatible with the following automated insulin delivery systems, or insulin pumps: * Insulet's Omnipod(R) 5 with both the FreeStyle Libre 3 Plus and the FreeStyle Libre 2 Plus sensors * Tandem Diabetes Care's t:slim X2 insulin pump with the FreeStyle Libre 3 Plus sensor * mylife Diabetes Care's YpsoPump insulin pump with the FreeStyle Libre 3 Plus sensor * MiniMed(TM) 780G system with the Instinct sensor, made exclusively by Abbott and distributed by Medtronic Hybrid closed loop systems like these combine a CGM with an insulin pump to automatically adjust insulin delivery based on glucose readings. They help people spend less time managing their condition and more time focusing on the things that matter to them. Libre technology provides real-time, personalised insights to help people understand how food, activity and medications affect their bodies. The latest Libre innovation is the world's first dual glucose-ketone sensor, which monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis, a serious diabetes-related complication. Graeme Scott, 58, from Angus, who lives with type 1 diabetes said: "My life has changed immensely for the better since starting on a hybrid closed loop system. Having my sensor and pump working together gives me greater confidence and flexibility day-to-day, helping reduce the burden of managing diabetes. The technology means I spend less time thinking about my glucose levels and more time focusing on the things I enjoy. I'm running my own life instead of letting diabetes run it for me." Julia Hammac, General Manager for Abbott's diabetes care business in the UK, said: "For people living with type 1 diabetes, having access to technologies that work seamlessly together can make a meaningful difference to day-to-day diabetes management. By expanding our hybrid closed loop partnerships, we're giving people more choice in how they manage their condition and helping make advanced diabetes technologies more accessible through connected care solutions." Hilary Nathan, Director of Policy and Communications at Breakthrough T1D said: "For many people living with type 1 diabetes, technology is part of everyday life. Having choice really matters. Everyone's experience of diabetes is different, and what works brilliantly for one person may not be right for another. We welcome developments that give people more options and greater flexibility in how they manage their condition, allowing them to choose technology that fits their individual needs, preferences and lives. Ultimately, we want to see a technology landscape shaped around the people who use it, with the freedom to choose the tools that work best for them and today's announcement helps us take one step further towards that." *Data on File, Abbott Diabetes Care

Yahoo Finance
Sep 9th, 2026
Tandem Diabetes rises 59% as Mobi tubeless pump awaits FDA clearance

Tandem Diabetes Care is positioned for growth through expanding product choices and a pay-as-you-go reimbursement model that lowers upfront costs whilst supporting higher recurring supply revenue. The company submitted a 510(k) for its Mobi tubeless pump targeting a 2026 launch and received FDA approval to begin a pivotal study for its fully closed-loop AIDANET programme. In the second quarter of 2026, pharmacy sales reached 10% of US sales, up from 6% in the first quarter, with formulary coverage at approximately 45%. Tandem reaffirmed its 2026 sales guidance of $1.065-$1.085 billion. The stock has risen 59% over the past year, against a 5.4% industry decline. The company holds a Zacks Rank #3 (Hold) with a market capitalisation of $1.05 billion.